Connection details for the SENS-601 Program Day are as follows: Date and time: September 22, 2026, at 2:30pm CET (8:30am ET) ...

A growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving ...

Company reports US$522K in July sales, US$403K in August sales, and US$2.07M in sales for the first eight months of 2026, ...

The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for dersimelagon for filing and ...

MINNEAPOLIS, MN – September 16, 2026 – Evia Bio, Inc., a life science company advancing next-generation cryopreservation ...

September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused ...

Interim data show high adherence and usability for remote, multimodal brain monitoring in borderline personality disorder and ...

Bristol Myers Squibb acquired the degrader-antibody conjugate from Orum Therapeutics in 2023 for $100 million upfront and the possibility of up to $80 million more in milestones.

Electra Therapeutics has exceeded its initial fundraising plans as it becomes the 26th biotech to debut publicly this year and outlines pivotal development plans for its monoclonal antibody ...

Big Pharma needs more—not fewer—bold bets on rare and difficult diseases after Novartis’ efforts to invest in muscular ...

A new five-year biotech plan has been released by the Chinese government, revealing ambitious goals such as achieving five blockbuster medicines on the global markets in that time.

With just over $10 million in cash available to fuel operations through the end of the year, Longeveron is undertaking a ...